Thursday, September 23, 2010

CytomX Gets $30M

San Francisco-based CytomX Therapeutics, a firm developing antibody technology, announced Thursday that it has raised $30M in a Series B funding round. The round was led by Third Rock Ventures, and also included the Roche Venture Fund. As part of the funding, the firm said that Third Rock's Neil Exter and Charles Homcy have joined the company's board of directors. The firm will use the funding to further develop its antibody platform. More information »